Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.53 |
| ▸ | PDE4A | P27815 | 2/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.49 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.49 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.49 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.49 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.49 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.49 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19402410 | 0.90 | KDM1A (0.58) | KDM1AGPR119PDE4BPDE4APDE4C | |
| SCHEMBL74564 | 0.87 | KDM1A (0.57) | KDM1AGPR119PDE4BPDE4APDE4C | |
| SCHEMBL19839235 | 0.87 | PDE4B (0.64) | KDM1AGPR119EPHX2PDE4BPDE4A | |
| SCHEMBL31726619 | 0.86 | GPR119 (0.62) | KDM1AGPR119PDE4BPDE4APDE4C | |
| SCHEMBL69206 | 0.86 | KDM1A (0.56) | KDM1AGPR119PDE4BPDE4APDE4C | |
| SCHEMBL68971 | 0.86 | KDM1A (0.56) | KDM1AGPR119EPHX2PDE4BPDE4A | |
| SCHEMBL3103045 | 0.86 | RBP4 (0.63) | KDM1AGPR119PDE4BPDE4APDE4C | |
| SCHEMBL5098530 | 0.85 | KDM1A (0.55) | KDM1AGPR119PDE4BPDE4APDE4C | |
| SCHEMBL71246 | 0.84 | EPHX2 (0.56) | KDM1AGPR119EPHX2KDM4E | |
| SCHEMBL5454387 | 0.84 | GPR119 (0.57) | KDM1AGPR119PDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268687-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-08 | — | — | US | disclosed |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-12098146-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-24 | — | — | US | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-113906019-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-3914593-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| WO-2020154571-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020154571-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020041100-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | KDM1A 1876/4885GPR119 3998/4885EPHX2 597/4885 |
| US-12268687-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | KDM1A 1876/4885GPR119 3998/4885EPHX2 597/4885 |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, RBP4, RBP1 | KDM1A 4682/4885GPR119 110/4885EPHX2 2320/4885 |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | KDM1A 1876/4885GPR119 3998/4885EPHX2 597/4885 |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | KDM1A 1876/4885GPR119 3998/4885EPHX2 597/4885 |
| US-12098146-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | KDM1A 1876/4885GPR119 3998/4885EPHX2 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.